has anyone died from glp-1 Nurse's death linked to weight-loss drug Mounjaro approved on NHS GLP-1 receptor agonists—the class of
Description
Check out the sector heatmap on MarketBeat
Discontinue use if the patient develops jaundice or other manifestations suggestive of liver dysfunction
Across much of the South and Midwest, the combination of high obesity prevalence, lower wages, and limited insurance coverage creates what could be described as GLP-1 deserts regions where access is constrained not just by price, but by insurance exclusions and state-level policy decisions
Heterogeneous results across the trials mean the evidence is suggestive, not conclusive
Overweight and obesity, in particular, intra-abdominal adiposity, are associated with various cardiometabolic conditions including type 2 diabetes (T2D), dyslipidemia, hypertension, atherosclerotic cardiovascular disease, and heart failure [2, 3]
